We are live on ! Find out more
WHWK icon

Whitehawk Therapeutics

40 hedge funds and large institutions have $19.4M invested in Whitehawk Therapeutics in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

36% more capital inflows, than outflows

Capital inflows: $12.5M | Capital outflows: $9.23M

21% more funds holding

Funds holding: 33 → 40 (+7)

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

0.49% more ownership

Funds ownership: 41.47% → 41.97% (+0.49%)

Holders
40
Holders Change
+7
Holders Change %
+21.21%
% of All Funds
0.7%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
12
Increased
10
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

WHWK Hedge Fund Activity: Q4 2020 in Review

40 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2020, worth a combined $19.4M — down 26% from $26.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new WHWK positions and 5 closed out — a net gain of 7 holders — while 10 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.19M. The largest seller was Ikarian Capital, cutting an estimated $4.94M.

  • 40 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2020, up from 33 in Q3 2020.
  • Funds reported $19.4M of Whitehawk Therapeutics stock for Q4 2020, down 26% quarter-over-quarter.
  • 12 funds opened new Whitehawk Therapeutics positions in Q4 2020 and 5 closed out, a net change of +7 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $2.19M added.
  • The largest Whitehawk Therapeutics seller in Q4 2020 was Ikarian Capital, an estimated $4.94M sold.

Based on aggregated 13F filings for Q4 2020.